PharmaResources (Shanghai) Co. Ltd. A Working Capital to Net Assets Ratio
PharmaResources (Shanghai) Co. Ltd. A working capital to net assets ratio. PharmaResources (Shanghai) Co. Ltd. A (301230) has a Working Capital to Net Assets ratio of 41.2% as of March 2026. Working capital of CN¥424.38 Million (current assets of CN¥578.13 Million minus current liabilities of CN¥153.75 Million) is measured against net assets of CN¥1.03 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of PharmaResources (Shanghai) Co. Ltd. A to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of PharmaResources (Shanghai) Co. Ltd. A (2020–2025)
Working capital to net assets ratio of PharmaResources (Shanghai) Co. Ltd. A from 2020 to 2025. This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the ratio stands at 41.2%, reflecting working capital of CN¥424.38 Million against net assets of CN¥1.03 Billion CNY. See 301230 days of operational coverage to measure how many days the company can operate on defensive assets alone.
PharmaResources (Shanghai) Co. Ltd. A Working Capital to Net Assets Ratio by Year (2020–2025)
PharmaResources (Shanghai) Co. Ltd. A working capital to net assets ratio by year from 2020 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for PharmaResources (Shanghai) Co. Ltd. A from 2020 to 2025, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see PharmaResources (Shanghai) Co. Ltd. A (301230) total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 40.8% | CN¥409.88 Million | CN¥1.00 Billion | CN¥582.10 Million | CN¥172.21 Million | ▼ -0.7 pp |
| 2024 | 41.5% | CN¥428.92 Million | CN¥1.03 Billion | CN¥554.32 Million | CN¥125.40 Million | ▼ -6.8 pp |
| 2023 | 48.3% | CN¥540.10 Million | CN¥1.12 Billion | CN¥731.32 Million | CN¥191.22 Million | ▼ -26.8 pp |
| 2022 | 75.1% | CN¥835.66 Million | CN¥1.11 Billion | CN¥936.53 Million | CN¥100.87 Million | ▲ +32.5 pp |
| 2021 | 42.6% | CN¥148.54 Million | CN¥348.44 Million | CN¥277.21 Million | CN¥128.67 Million | ▼ -11.2 pp |
| 2020 | 53.8% | CN¥141.68 Million | CN¥263.18 Million | CN¥231.03 Million | CN¥89.36 Million | — |